Rubius Therapeutics to Provide Strategic Update
September 12 2022 - 4:30PM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced that the Company plans to
provide a strategic update and host an investor teleconference and
webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.
Investor Teleconference & Webcast
An audio webcast will be available on the Events and
Presentations page within the Investors and Media section of the
Rubius Therapeutics website and can be directly accessed here. An
archived webcast will be accessible for 90 days after the
event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical
company developing a new class of medicines called Red Cell
Therapeutics™. The Company’s proprietary RED PLATFORM® was designed
to biologically engineer and culture Red Cell Therapeutics™ that
are selective, potent and off-the-shelf allogeneic cellular
therapies for the potential treatment of several diseases across
multiple therapeutic areas. Rubius’ initial focus is to advance
RCT™ product candidates for the treatment of cancer and autoimmune
diseases by leveraging two distinct therapeutic modalities — potent
cell-cell interaction and tolerance induction.
Rubius Therapeutics was named among the 2021 Top Places to
Work in Massachusetts by the Boston Globe, and its manufacturing
site was recently named 2022 Best Places to Work in Rhode
Island by Providence Business News. For more information,
visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us
on Facebook.
Investor and Media ContactLori Murray, Chief
Corporate Affairs Officer lori.murray@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2024 to May 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From May 2023 to May 2024